CAS: 784150-41-0; 6-Bromo-4-Chloro-7H-Pyrrolo[2,3-D]Pyrimidine
该化合物是热循环化合物,其特点是其引信的火花和火利因环,具有独特的化学特性;该化合物具有6个位置的溴原子和4个位置的氯原子,影响其反应和药用化学的潜在应用;它一般在室温下是固体,在有机溶剂中可能表现出中等溶解性;卤素在其结构中的存在可加强其生物活动,使其成为各种药物应用的候选产品,特别是在发展脂酶抑制剂或其他治疗剂方面;此外,其结构特征可能允许与生物目标发生相互作用,从而导致药物发现的潜在用途;与许多外生循环一样,它也可能参与各种化学反应,包括在合成有机化学中有价值的核循环替代和组合反应;由于存在卤素和化合物的潜在生物活动,应当遵守安全和处理预防措施.
- 英文名称6-Bromo-4-Chloro-7H-Pyrrolo[2,3-D]Pyrimidine
- 中文名称6-溴-4-氯-7H-吡咯并[2,3-d]嘧啶
- IUPAC名称6-bromo-4-chloro-7H-pyrrolo[2,3-d]pyrimidine
- 其它别名4-氯-6-溴-7H-吡咯并[2,3-D]嘧啶; 6-Bromo-4-Chloro-1H-Pyrrolo[2,3-D]Pyrimidine
- CAS编号784150-41-0
- MFCD编号:MFCD08276174
- 分子式:C6H3BrClN3分子量:232.47
- 产品CID: 1779176
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡咯类化合物
相似化合物
3680-69-1 22276-95-5 115093-90-8MSDS等安全信息
上下游产品
6-bromo-4-chloro-7-(benzenesulfonyl)-7H-pyrrolo[2,3-d]pyrimidine 6-bromo-4-chloro-7-methylpyrrolo[2,3-d]pyrimidine 6-({6-[(4-chlorophenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-1,3-benzothiazol-2(3H)-one N-methyl-3-[(6-phenyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzenesulfonamide合成工艺路线路线简述
📜4-氯-7-(苯基磺酰基)-7H-吡咯并[2,3-D]嘧啶置于1,2-二溴四氯乙烷,Potassium Tert-Butylate,Lithium Diisopropyl Amide体系中,用 四氢呋喃 作为反应溶剂,化学反应 2.0H,反应生成 6-溴-4-氯-7H-吡咯并嘧啶
参考文献:Identification Of Purines And 7-Deazapurines As Potent And Selective Type I Inhibitors Of Troponin I-Interacting Kinase (Tnni3K)
标题:Identification Of Purines And 7-Deazapurines As Potent And Selective Type I Inhibitors Of Troponin I-Interacting Kinase (Tnni3K)
摘要:A Series Of Cardiac Troponin I-Interacting Kinase (Tnni3K) Inhibitors Arising From 34(9H-Purin-6-yl)Amino)-N-Methyl-Benzenesulfonamide (1) Is Disclosed Along With Fundamental Structure Function Relationships That Delineate The Role Of Each Element Of 1 For Tnni3K Recognition. An X-Ray Structure Of 1 Bound To Tnni3K Confirmed Its Type I Binding Mode And Is Used To Rationalize The Structure Activity Relationship And Employed To Design Potent,Selective,And Orally Bioavailable Tnni3K Inhibitors. Identification Of The 7-Deazapurine Heterocycle As A Superior Template (Vs Purine) And Its Elaboration By Introduction Of C4-Benzenesulfonamide And C7-And C8-7-Deazapurine Substituents Produced Compounds With Substantial Improvements In Potency (>1000-Fold),General Kinase Selectivity (10-Fold Improvement),And Pharmacokinetic Properties (>10-Fold Increase In Podnauc). Optimal Members Of The Series Have Properties Suitable For Use In In Vitro And In Vivo Experiments Aimed At Elucidating The Role Of Tnni3K In Cardiac Biology And Serve As Leads For Developing Novel Heart Failure Medicines.
DOI:10.1021/acs.Jmedchem.5B00931
